by staining the cells for PD-L1 marker. The data was presented at the annual San Antonio Breast Cancer Symposium (SABCS) in December 2024, and is titled: PD-L1 Upregulation in Circulating Tumor ...

A new research paper was published in , Volume 16, on April 24, 2025, titled "PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region." ...

In the article appearing in the AACR Journal, researchers at the Henry Ford Health Pancreatic Cancer Center, found that Black ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven ...

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the ...

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of ...

Top-line results from CheckMate -026 showed that Opdivo given as a monotherapy to treatment naïve patients whose tumour expressed the PD-L1 marker at ≥ 5% didn’t meet its primary endpoint of ...

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

CytoDyn is also interested in the expressions of CCR5 and PD-L1 markers on the tumor. These markers can change over time. LifeTracDx ® can provide this information by a blood test - no tissue is ...

by staining the cells for PD-L1 marker. CreatvBio (PRNewsfoto/Creatv MicroTech, Inc.) The data of 36 patients showed that a decrease in CTCs/CAMLs numbers significantly correlated with better ...